Literature DB >> 18976464

Giant retroperitoneal liposarcoma.

Angel Herrera-Gómez1, César Ortega-Gutiérrez, Alejandro Mohar Betancourt, Kuauhyama Luna-Ortiz.   

Abstract

BACKGROUND: Liposarcoma is the most frequent histopathological variety of the retroperitoneum, surgery is the gold standard for treatment. CASE
PRESENTATION: We present the case of a 24-year-old male who was diagnosed with a giant retroperitoneal liposarcoma. The patient received palliative treatment due to non-resectability on the basis of chemotherapy. We decided to perform surgery after no benefit was received with systemic treatment. Complete macroscopic resection of the tumor was performed, without multi-organ resection. The patient is currently alive and disease free at 14 months of evolution.
CONCLUSION: Retroperitoneal liposarcomas represent a unique situation and require a more aggressive surgical approach including multiple resections for recurrences. Based on the ability of the patient to tolerate the procedure, surgery is suggested to evaluate resectability of the tumor. We must take into consideration whether prolonged survival will be attained and tumor removal will result in palliation of symptoms.

Entities:  

Mesh:

Year:  2008        PMID: 18976464      PMCID: PMC2644689          DOI: 10.1186/1477-7819-6-115

Source DB:  PubMed          Journal:  World J Surg Oncol        ISSN: 1477-7819            Impact factor:   2.754


Background

Liposarcomas are neoplasms of mesodermic origin derived from adipose tissue and correspond to 10–14% of all soft tissue sarcomas. They represent < 1% of all malignant tumors [1,2]. The most frequent subtypes are liposarcoma (41%), leiomyosarcoma (28%), malignant fibrous histiocytoma (7%), fibrosarcoma (6%) and tumors of the peripheral nerve sheath (3%) [3]. Retroperitoneal liposarcomas alone comprise 0.07–0.2% of all neoplasias4. Approximately 85% of these are malignant, with soft-tissue sarcomas representing 35% of this group. Liposarcoma is the most frequent histopathological variety of the retroperitoneum [2]. It presents with inherent characteristics in relation to its deep localization and slow expansive growth. Average diameter of the tumor is 20–25 cm with a weight of 15–20 kg [4]. There is compromise of the adjacent organs in up to 80% of the cases [4,5]. Surgery is the gold standard for treatment of liposarcoma. Retroperitoneal liposarcoma is a distinct clinical entity that requires a more aggressive surgical approach, including multiple resections or multiorgan resection with recurrences. There is a low incidence of distance metastasis (7%) compared to other histological subtypes that range from 15 to 34% [6]. The objective of this study is to report a case of giant retroperitoneal sarcoma.

Case presentation

A 24-year-old male presented with a 6-month evolution of his disease with abdominal pain, constipation, fever and a 20-kg weight loss. He received treatment for typhoid fever without improvement. For this reason, abdominal tomography was performed, demonstrating a heterogeneous lesion with zones of fat and solid density that entirely occupied the abdominal cavity, displacing retroperitoneal structures dorsally. CT-guided biopsy was performed at a different hospital and pathological report demonstrated liposarcoma. Colonoscopy was performed, demonstrating extrinsic compression at the level of the descending colon. The patient was sent to our Institution for further evaluation. Upon admission, the patient had a Karnofsky score of 90 and was classified as grade zero according to the status of the Eastern Cooperative Oncology Group (ECOG). He also presented with respiratory difficulty and distended abdomen due to solid, multilobulated tumor that extended from the epigastrium to the pelvic region without delineated borders. CT scan confirmed previous findings (Fig. 1). Histopathological review from the referring hospital demonstrated minute fragments of mature adipose tissue without atypia. This material was considered to be inadequate for diagnosis. For this reason, a new CT-guided biopsy was performed and a well-differentiated sclerosing-type liposarcoma was reported (Fig. 2). Because the patient's tumor had previously been considered nonresectable, he was referred to medical oncology where chemotherapy with ifosfamide and adriamycin was offered. Clinical and radiological responses were evaluated and reported stable disease. The patient completed six cycles of adriamycin and ifosfamide and was re-evaluated upon treatment completion. The patient continued with stable disease (no change in tumor size was documented either clinically or radiologically) without change in functional status according to Karnofsky index upon admission. At the conclusion of chemotherapy, supportive therapy vs. chemotherapy with etoposide and ifosfamide was proposed and the patient elected supportive therapy. An interdepartmental meeting was held and, in a joint decision with the patient, surgical exploration was decided upon. Surgery was performed with the patient in dorsal decubitus and a midline incision was made from the xyphoid to the pubis, revealing an 80 × 60-cm tumor that encompassed the entire retroperitoneal cavity, with lax adhesions to the descending colon and ureters, neovascularization and adherence to the bladder without multiorgan resection and with macroscopic free margins (Fig. 3). Complete resection of the tumor was performed. The patient had a satisfactory evolution and was discharged 48 h postsurgery without adjuvant treatment. The final histopathological report showed undifferentiated liposarcoma of the retroperitoneum (80 × 50 × 35 cm) weighing 18 kg.
Figure 1

CT scan. Heterogeneous lesion is observed with zones of fat and solid density that entirely occupy the abdominal cavity, displacing retroperitoneal structures dorsally.

Figure 2

Well-differentiated sclerosing liposarcoma.

Figure 3

Retroperitoneal tumor (80 × 60 cm), weighing 18 kg. Complete resection.

CT scan. Heterogeneous lesion is observed with zones of fat and solid density that entirely occupy the abdominal cavity, displacing retroperitoneal structures dorsally. Well-differentiated sclerosing liposarcoma. Retroperitoneal tumor (80 × 60 cm), weighing 18 kg. Complete resection. The patient is being followed-up every 3 months. At 6 months post-surgery, a new CT scan was done and there was no evidence of disease (Fig. 4). Currently, at 14 months of follow-up, the patient is asymptomatic and disease free.
Figure 4

CT scan. No evidence of tumor activity is demonstrated. Localization of intraabdominal organs is adequate.

CT scan. No evidence of tumor activity is demonstrated. Localization of intraabdominal organs is adequate.

Discussion

Liposarcoma is the most frequent histological type of retroperitoneal sarcoma, corresponding to 41% of these tumors [4,5]. It has been reported that 20% of the tumors are > 10 cm at the time of diagnosis [3]; however, few cases of retroperitoneal liposarcomas exist that can be considered as giant [4,6-9]. The case we present may be considered among the largest tumors reported for this histology. Clinically, these tumors tend to present with diffuse abdominal pain accompanied by anorexia and weight loss and increase in abdominal girth. The most characteristic sign is a painless abdominal mass detected in ~78% of the cases. Abdominal symptomatology is due to compression of the organs, similar to that reported with the present case [3,4]. It is clear that our patient presented all the signs and symptoms specific for these tumors due to the size of the abdominal mass. The tumor was initially considered nonresectable and, therefore, systemic treatment with chemotherapy was decided upon, with the goal of reducing tumor load. Various chemotherapy regimens have been described based on mesna, doxorubicin, ifosfamide, dacarbazine and paclitaxel. However, their use is limited for recurrent metastatic disease or palliation. Survival benefits have not been demonstrated [10]. Due to the large tumor load and probable multiorgan involvement, we initially considered palliative treatment for our patient. Because the patient did not demonstrate any beneficial effects from chemotherapy, the joint decision of the hospital committee, along with the patient, was to perform surgery. Complete resection of the tumor was performed. We are in agreement with Patrik et al. [6] who demonstrated that in liposarcomas > 10 cm, complete resection can be carried out in up to 70% of cases; however, in up to 50% of these cases, multiorgan resection is necessary in order to reach this goal [2]. The most frequent organ resected is the kidney (30%). In the case we report here, even with the large size of the tumor, organ resection was not necessary, because there was no infiltration to neighboring structures, only lax adhesions allowing adequate dissection of the tumor, as shown in Fig. 3. Radiotherapy (RT) was not considered in this case for two principal reasons: the first was due to the large tumor load and no demonstrable reduction in tumor size and, second, because of the probable gastrointestinal morbidity associated with such an extensive field as in this case. With regard to RT as complementary treatment, there is agreement for its palliative use in non-operable tumors or in cases of incomplete resection [7,8]. Although mesodermic tumors are radioresistant, liposarcoma is more radiosensitive [6]. Although it has been noted that RT may increase survival and disease-free interval [3,7,8], other authors reported that this treatment has not demonstrated long-term improvement in survival or specific disease in cases of complete macroscopic resections [6,8]. This occurs despite using intraoperative RT with the goal of increasing efficacy of the local dose with 50–60 Gy [7] and of minimizing toxicity to adjacent organs. In our case, because we were dealing with a well-differentiated primary liposarcoma that allowed complete resection, 5-year survival of 75–100% [9,11] has been described. Local failure occurs within 5 to 10 years after resection in up to 90% of the cases related to size of tumor, inability to achieve free margins and limitations of adjuvant treatment such as chemotherapy or RT [3,4]. We cannot compare these data with our report because our patient is disease free at 14 months of follow-up.

Conclusion

Retroperitoneal liposarcomas are a unique situation and require a more aggressive surgical approach including, when necessary, multiorgan resection or multiple resections with recurrences. In accordance with the ability of the patient to tolerate the procedure, surgery is suggested to evaluate tumor resectability, taking into consideration prolonged survival. After tumor removal, palliation of symptoms will be accomplished.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

AHG Carried out the surgery procedure, review the manuscript. COG Carried out the surgery and search for literature review and review manuscript. AMB was the pathologist for this case and review the article. KLO Carried out the surgery, write the article, analysis of the literature and review the article. All authors read and approved the final manuscript.

Consent

Written informed consent was obtained from the patient for publication of this case report.
  11 in total

1.  [Retroperitoneal tumors. Retroperitoneal myxoid liposarcoma. Report of a new case].

Authors:  P Azpiazu Arnaiz; I Muro Bidaurre; A De Frutos Gamero; E Castro Esnal; A Martín López; J I Asensio Gallego; J R Ribera Garbayo
Journal:  Arch Esp Urol       Date:  2000-03       Impact factor: 0.436

2.  [Retroperitoneal liposarcoma. Apropos of 3 cases].

Authors:  P L Guzmán Martínez-Valls; R Ferrero Doria; J López Alba; M Tomás Ros; F J Rodenas Moncada; J L Rico Galiano; J M Rodríguez de Ledesma Vega; L Fontana Compiano
Journal:  Arch Esp Urol       Date:  1997-06       Impact factor: 0.436

3.  Inflammatory variant of a well-differentiated retroperitoneal liposarcoma: case report of a rare giant variety.

Authors:  Prateek K Mehrotra; C S Ramachandran; Deep Goel; Vijay Arora
Journal:  Indian J Cancer       Date:  2006 Jan-Mar       Impact factor: 1.224

4.  [Giant retroperitoneal liposarcoma].

Authors:  Miguel Echenique-Elizondo; José Antonio Amondarain-Arratíbel
Journal:  Cir Esp       Date:  2005-05       Impact factor: 1.653

Review 5.  [Adipose retroperitoneal tumors. Apropos a giant myxoid liposarcoma].

Authors:  P Romero Pérez; W Rafie Mazketli; M Amat Cecilia; F J Merenciano Cortina; M Gonzalez Devesa
Journal:  Actas Urol Esp       Date:  1996-01       Impact factor: 0.994

6.  Improved survival following complete excision of retroperitoneal sarcomas.

Authors:  P C McGrath; J P Neifeld; W Lawrence; R M DeMay; S Kay; J S Horsley; G A Parker
Journal:  Ann Surg       Date:  1984-08       Impact factor: 12.969

Review 7.  Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution.

Authors:  J J Lewis; D Leung; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  1998-09       Impact factor: 12.969

8.  Operative management of primary retroperitoneal sarcomas: a reappraisal of an institutional experience.

Authors:  Imran Hassan; Saung Z Park; John H Donohue; David M Nagorney; Paul A Kay; Antonio G Nasciemento; Cathy D Schleck; Duane M Ilstrup
Journal:  Ann Surg       Date:  2004-02       Impact factor: 12.969

9.  Management of primary and recurrent soft-tissue sarcoma of the retroperitoneum.

Authors:  D P Jaques; D G Coit; S I Hajdu; M F Brennan
Journal:  Ann Surg       Date:  1990-07       Impact factor: 12.969

10.  Retroperitoneal sarcoma: the University of Florida experience.

Authors:  J W Kilkenny; K I Bland; E M Copeland
Journal:  J Am Coll Surg       Date:  1996-04       Impact factor: 6.113

View more
  13 in total

1.  Giant inflammatory variant of well-differentiated liposarcoma of retroperitoneum: a rare case report.

Authors:  Shubha P Bhat; Kishan H L Prasad; Rohan Shetty; Rajesh Ballal; Sunil Y Kumar; Panna Hegde
Journal:  Indian J Surg Oncol       Date:  2013-04-16

2.  A retrospective, single-center cohort study on 65 patients with primary retroperitoneal liposarcoma.

Authors:  Yi-Xi Wu; Jun-Yan Liu; Jia-Jia Liu; Peng Yan; Bo Tang; You-Hong Cui; Yong-Liang Zhao; Yan Shi; Ying-Xue Hao; Pei-Wu Yu; Feng Qian
Journal:  Oncol Lett       Date:  2017-12-05       Impact factor: 2.967

3.  Giant Retroperitoneal Liposarcoma Mimicking Ovarian tumour - A Case report.

Authors:  Sa Aji; Su Alhassan; Sa Ibrahim
Journal:  J West Afr Coll Surg       Date:  2011-04

4.  Management of high-grade retroperitoneal liposarcomas: personal experience.

Authors:  Marco Milone; Luigi Sossio Pezzullo; Giuseppe Salvatore; Martina Gilda Pezzullo; Maddalena Leongito; Ida Esposito; Francesco Milone
Journal:  Updates Surg       Date:  2011-04-01

5.  Huge retroperitoneal liposarcoma.

Authors:  Mohammad Reza Akhoondinasab; Mahmoud Omranifard
Journal:  J Res Med Sci       Date:  2011-04       Impact factor: 1.852

6.  Giant retroperitoneal liposarcoma: Case report and review of the literature.

Authors:  Antonio Caizzone; Edoardo Saladino; Francesco Fleres; Cosimo Paviglianiti; Francesco Iaropoli; Carmelo Mazzeo; Eugenio Cucinotta; Antonio Macrì
Journal:  Int J Surg Case Rep       Date:  2015-02-17

7.  Retroperitoneal tumor: giant cavernous hemangioma - case presentation and literature review.

Authors:  Jacek Zielinski; Ireneusz Haponiuk; Radoslaw Jaworski; Rafal Peksa; Ninela Irga-Jaworska; Janusz Jaskiewicz
Journal:  Kardiochir Torakochirurgia Pol       Date:  2016-12-30

8.  Giant retroperitoneal liposarcoma: a case report.

Authors:  Chavan Shahaji; Parasnis Amit; Punia Prashant; Tekade Sachin
Journal:  Case Rep Oncol Med       Date:  2012-11-26

9.  Tissue expander placement and adjuvant radiotherapy after surgical resection of retroperitoneal liposarcoma offers improved local control.

Authors:  Hyojun Park; Sanghoon Lee; BoKyong Kim; Do Hoon Lim; Yoon-La Choi; Gyu Seong Choi; Jong Man Kim; Jae Berm Park; Choon Hyuck David Kwon; Jae-Won Joh; Sung Joo Kim
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

10.  Dyspnea caused by a giant retroperitoneal liposarcoma: A case report.

Authors:  Argyrios Ioannidis; Christos Koutserimpas; Michael Konstantinidis; Ioannis Drikos; Panagiotis Voulgaris; Nikolaos Economou
Journal:  Oncol Lett       Date:  2018-05-24       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.